40
Participants
Start Date
May 31, 2006
Primary Completion Date
April 30, 2008
Study Completion Date
April 30, 2008
Certolizumab pegol (CZP)
Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.
Certolizumab pegol (CZP)
Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.
Certolizumab pegol (CZP)
Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol 400 mg at Weeks 0, 2 and 4.
Aichi-Gun
Nagoya
Toyoake
Toyohashi
Kashiwa
Sakura
Chikusino
Fukuoka
Asahikawa
Sapporo
Nishinomiya
Kagoshima
Yokohama
Miyazaki-Gun
Nagasaki
Niigata
Kurashiki
Tyuto-gun
Osaka
Suita
Ōtsu
Shinjyuku/Tokyo
Shinjyuku
UCB Japan Co. Ltd.
INDUSTRY